Mosaic Therapeutics
Mosaic Therapeutics is dedicated to resolving cancer’s complexity through the power of drug combinations, redefining cancer therapy with a focus on targeted, biomarker-defined treatments. Built upon 15 years of research at the Wellcome Sanger Institute, the company combines experimental and computational biology to develop more effective and faster cancer treatments, aiming to improve patient outcomes and accelerate development timelines.
Industries
Nr. of Employees
small (1-50)
Mosaic Therapeutics
MosaicTX Therapeutics, Wellcome Genome Campus, Cambridge, United Kingdom, CB10 1DR
Products
Preclinical pipeline of targeted oncology therapies
A set of biomarker-defined combination therapy candidates identified through integrated CRISPR screening, combination drug screening and computational prediction, advanced through preclinical development.
In-licensed clinical-stage oncology programs
Clinical-stage oncology assets acquired for redevelopment as proprietary combination therapies.
Preclinical pipeline of targeted oncology therapies
A set of biomarker-defined combination therapy candidates identified through integrated CRISPR screening, combination drug screening and computational prediction, advanced through preclinical development.
In-licensed clinical-stage oncology programs
Clinical-stage oncology assets acquired for redevelopment as proprietary combination therapies.
Services
Identify and advance biomarker-defined combination therapy candidates through experimental and computational workflows.
Acquire clinical-stage oncology assets for redevelopment as biomarker-guided combination therapies and integrate them into the development pipeline.
Identify and advance biomarker-defined combination therapy candidates through experimental and computational workflows.
Acquire clinical-stage oncology assets for redevelopment as biomarker-guided combination therapies and integrate them into the development pipeline.
Expertise Areas
- Combination therapy discovery
- Preclinical oncology research
- Genome-scale genetic screening
- Patient-derived models and organoids
Key Technologies
- Genome-scale CRISPR screening
- CRISPR-Cas9 genetic screens
- Patient-derived tumour organoids
- High-throughput combination drug screening
News & Updates
Mosaic announced a $28 million Series A investment round to advance its preclinical pipeline of targeted oncology therapies.
Mosaic announced a $28 million Series A investment round to advance its preclinical pipeline of targeted oncology therapies.